These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23695478)

  • 1. Advances in regulatory science at the Food and Drug Administration.
    Psaty BM; Goodman SN; Breckenridge A
    JAMA; 2013 May; 309(20):2103-4. PubMed ID: 23695478
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing the cardiovascular safety of diabetes therapies.
    Goldfine AB
    N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
    [No Abstract]   [Full Text] [Related]  

  • 3. Two-stage drug approval would reduce the risks.
    Frantz JA
    Nature; 2005 May; 435(7039):143. PubMed ID: 15889063
    [No Abstract]   [Full Text] [Related]  

  • 4. Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval.
    Wallach JD; Zhang AD; Skydel JJ; Bartlett VL; Dhruva SS; Shah ND; Ross JS
    JAMA Netw Open; 2021 Nov; 4(11):e2133667. PubMed ID: 34751763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 6. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA Warns Against Unregulated Products.
    Aschenbrenner DS
    Am J Nurs; 2018 Mar; 118(3):22-23. PubMed ID: 29470211
    [No Abstract]   [Full Text] [Related]  

  • 8. Preventing postmarketing changes in recommended doses and marketing withdrawals.
    Peck C
    Ernst Schering Res Found Workshop; 2007; (59):209-16. PubMed ID: 17117726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
    Psaty BM; Meslin EM; Breckenridge A
    JAMA; 2012 Jun; 307(23):2491-2. PubMed ID: 22563032
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA's first active medical product surveillance eyes antidiabetic-MI link.
    Thompson CA
    Am J Health Syst Pharm; 2011 Apr; 68(7):550-1. PubMed ID: 21411791
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA drug-review, surveillance processes under scrutiny.
    Miller JL
    Am J Health Syst Pharm; 1999 Mar; 56(5):404, 406, 408. PubMed ID: 10096696
    [No Abstract]   [Full Text] [Related]  

  • 12. Tuft's report backs FDA fast-track, but post-marketing concerns loom.
    Vastag B
    Nat Biotechnol; 2006 May; 24(5):478. PubMed ID: 16680113
    [No Abstract]   [Full Text] [Related]  

  • 13. How pharmaceuticals are developed.
    Vander Elst E
    J Am Dent Assoc; 1994 Jan; 125 Suppl():40S-44S. PubMed ID: 8294674
    [No Abstract]   [Full Text] [Related]  

  • 14. Preapproval Promises to Voluntarily Withdraw FDA-Approved Drugs.
    Fernandez Lynch H; Sachs RE
    JAMA; 2022 Dec; 328(24):2392-2393. PubMed ID: 36480185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 16. The Food and Drug Administration's use of postmarketing (Phase IV) study requirements: exception to the rule?
    Steenburg C
    Food Drug Law J; 2006; 61(2):295-383. PubMed ID: 16903034
    [No Abstract]   [Full Text] [Related]  

  • 17. Striking the right balance.
    Nat Rev Drug Discov; 2006 Nov; 5(11):879. PubMed ID: 17117516
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

  • 19. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
    Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conducting prospective sequential surveillance in real-world dynamic distributed databases.
    Maro JC; Eworuke E; Hou L; Welch EC; Goulding MR; Izem R; Lee JY; Toh S; Fireman B; Nguyen MD
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1331-1335. PubMed ID: 32449261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.